Paper: Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Program: Oral and Poster Abstracts Type: Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations Hematology Disease Topics & Pathways: Adult, Combination therapy, Lymphoid Leukemias, CLL, Diseases, Treatment Considerations, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease Nitin Jain, MD 1, Alessandra Ferrajoli, MD 1, Mahesh Swaminathan, MD 1, Patrick K. Reville, MD, MPH 1, Jan A. Burger, MD, PhD 1, Vanthana Bharathi,
